The next major breakthrough in Immuno-oncology
With a proprietary human synthetic chromosome (hSynC) as a carrier for antitumoral factors (OncoSynC) introduced into the patient’s own T-cells, CarryGenes’ Cromo-T will create a state of long-term vaccination against the patient’s tumor using immune cells loaded with an enhanced tumor-killing capacity.
With a passion for science CarryGenes merges technologies as well as expertise in immunotherapy and chromosome bioengineering to produce a novel therapeutic with advanced safety mechanisms
With a lifelong passion for science and improving human health, the team has a joint ambition to use their knowledge to improve human health. Today there are no similar solutions to fight cancer.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Stockholm
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://carrygenes.com
- Keywords
- Haga.
- HQ
- Stockholm
Carrygenes Questions
Carrygenes's website is http://carrygenes.com
Carrygenes's LinkedIn profile is https://se.linkedin.com/company/carrygenes
Carrygenes has
4 employees.
View email and phone details for 4
employees at Carrygenes.
Carrygenes's industry is
Biotechnology Research
Carrygenes's top competitors are
Basic Genomics Ab,
Modus Therapeutics Holding Ab,
Cybergene,
Apotekskonsulterna Ab,
Incredible,
Pharmarelations,
Divide Ab (Publ),
Asclepiceutical Ai,
Giftinformationscentralen,
New Nordic Beverage.
Carrygenes's categories are Biotechnology Research
Carrygenes's founding year is 2018
